Trial Profile
Reduction of Vascular Inflammation and Coronary Atherosclerosis With AGI-1067, a V-Protectant, Reduces Cardiovascular Events in Patients With Coronary Artery Disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 Aug 2020
Price :
$35
*
At a glance
- Drugs Succinobucol (Primary)
- Indications Acute coronary syndromes; Cardiovascular disorders; Coronary artery disease; Type 2 diabetes mellitus
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms ARISE
- Sponsors AtheroGenics
- 05 Sep 2005 New trial record.